Plasma Cell Myeloma FISH Panel by Fluorescence In Situ Hybridization (FISH) Analysis
p53 gene/Cen17 for 17p deletion, RB1 gene (13q14), LAMP1 gene (13q34) for monosomy 13/13q deletion, Cen3/Cen7 for detection of hyperdiploidy, CCNDI and IgH gene rearrangement, CKS1B/CDKN2 (p18) Amplification/Deletion, With Chrom: EPIC: LAB6471, SOFT: GMYEP, Without Chrom: EPIC: LAB5125, SOFT: GMYE2
Specimen Collection Criteria
Collect: Bone marrow aspirate in a Green-top Sodium Heparin tube. (Min: 1.0 mL)
A copy of the requisition must be sent with the specimen.
FedEx Shipping Instructions
Transport 1-2 mL bone marrow at room temperature. If the specimen will not be received at the testing laboratory within 48 hours of collection, transport refrigerated. Do not fix or freeze the specimen. A pathology report for the patient must be provided.
Read our complete shipping instructions.
Physician Office/Drawsite Specimen Preparation
Do not freeze specimen. Maintain specimens at room temperature (20-25°C or 68-77°F) prior to courier pickup. For delays in transport (greater than 48 from the time of collection), refrigerate (2-8°C or 36-46°F) the specimen.
Preparation for Courier Transport
Transport: Bone marrow, at room temperature (20-25°C or 68-77°F) or refrigerated (2-8°C or 36-46°F).
- Specimens arriving in the Laboratory 4 days or more following the original collection date.
- Fixed or frozen specimens.
Specimen Stability for Testing:
Room Temperature (20-26°C or 68-78.8°F): 48 hours
Refrigerated (2-8°C or 36-46°F): 96 hours
Frozen (-20°C/-4°F or below): Unacceptable
Specimen Storage in Department Prior to Disposal:
Refrigerated (2-8°C or 36-46°F): 7 days. A backup culture is maintained for two weeks after the final report has been issued.
Royal Oak Clinical Cytogenomics Laboratory.
Monday - Friday, 8:00 a.m. - 5:00 p.m.
Results available within 7 days of receipt in the Laboratory.
Positive or negative for a neoplastic clone. An interpretative report will be provided.
Fluorescence In Situ Hybridization (FISH) Analysis.
Loss of chromosome 13/13q- is associated with shorter survival, lower response rates to treatment, and is considered an independent prognostic variable. Gain of chromosomes 3 and 7 is found in >90% of hyperdiploid cases. Hyperdiploid PCM patients seem to have a better outcome than nonhyperdiploid patients. Three major specific IgH translocations, t(11;14)(q13;q32), t(4;14)(p16.3;q32), and (14;16)(q32;q23), are identified in PCM. The t(4;14) and t(14;16) are cryptic translocations found in less than 15% of patients and can only be detected accurately utilizing the FGFR3/IgH and MAF/IgH FISH dual fusion FISH probes, respectively (which can be performed reflexively). Both the t(4;14) and t(14;16) are associated with hypodiploidy, an adverse disease outcome with shorter survival, and aggressive clinical features. The t(11;14) is associated with a favorable prognosis. Deletion of 17p13 (p53 gene) also confers a negative risk factor in PCM. Amplification (upregulation) of the CKS1B gene is associated with disease progression and a poorer prognosis, as is deletion of the tumor suppressor gene CDKN2C.
Conventional cytogenetic analysis in plasma cell myeloma (PCM) is difficult due to patchy bone marrow infiltration and low proliferation of the malignant plasma cells. An abnormal karyotype is found in 30-40% of cases, more often in advanced stages than in newly diagnosed patients. Two distinct cytogenetics groups are recognized: a hyperdiploid group with 47 chromosomes or greater observed in around 60% of cases and a nonhyperdiploid group with 46 chromosomes or less, observed in the remaining 40%. Nonhyperdiploid PCM has a higher prevalence of IgH/14q32 translocations, monosomy 13/13q deletion, and 17p deletion. Clinically, this cytogenetics classification is valuable, since FISH analysis has demonstrated that chromosome aberrations can be found in the majority of PCM cases. This myeloma FISH panel includes enumeration probes for chromosomes 3 and 7 to screen for ploidy, as well as probes to detect monosomy 13/13q deletion, p53 gene deletion, and common IgH translocations. This methodology yields significant prognostic information for risk assessment and treatment stratification in patients with PCM.
- Dewald GW et al. (2005) Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 106(10), 3553-3558.
88271x8 (DNA probe, each), 88275x5 (Interphase analysis, 100-300 cells).
With Chrom: EPIC: LAB6471, SOFT: GMYEP, Without Chrom: EPIC: LAB5125, SOFT: GMYE2